For US Healthcare Professionals Only
Your goal in adults with hATTR1:
STOP
STOP
POLYNEUROPATHY PROGRESSION*
START
IMPROVING QUALITY OF LIFE†
Individual responses may vary.
*As measured by mNIS+7 scores.
†As measured by Norfolk QoL-DN scores.
Discover the efficacy of WAINUA
Learn more about dosing and administration
Explore access and support
Sign up for the latest information about WAINUA
Fields marked with an * are required.
AstraZeneca is committed to helping healthcare professionals provide appropriate care for their patients. Please provide us with this information so that we can keep your records up to date and can send you any information that you request. If in the future you no longer want to receive health-related materials from AstraZeneca, please call 1-800-236-9933. Please visit www.azprivacynotice.com to review our Privacy Notice.
You may report side effects related to AstraZeneca products .
AstraZeneca is committed to helping healthcare professionals provide appropriate care for their patients. Please provide us with this information so that we can keep your records up to date and can send you any information that you request. If in the future you no longer want to receive health-related materials from AstraZeneca, please call 1-800-236-9933. Please visit www.azprivacynotice.com to review our Privacy Notice.
You may report side effects related to AstraZeneca products.
FOOTNOTES AND ABBREVIATIONS
hATTR, hereditary transthyretin-mediated amyloidosis; mNIS+7, modified Neuropathy Impairment Score +7; Norfolk QoL-DN, Norfolk Quality of Life-Diabetic Neuropathy.
REFERENCE
- 1. WAINUA® (eplontersen) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
